glp-1 dpp 4 Dipeptidyl peptidase inhibitors in the treatment of type 2 diabetes mellitus Cardiovascular effects of DPP-4 inhibition:

Add only 1 mL to the same vial, and the strength doubles to 10 mg per mL

Participants in this experiment complained of headache, fatigue, insomnia, intestinal disturbances, and numbness and tingling of their hands and feet (13)

Additional considerations include: Dietary quality changes during weight loss programmes Increased urinary magnesium excretion in poorly controlled diabetes (though GLP-1 therapy typically improves glycaemic control) Concurrent medications that may affect magnesium status, such as proton pump inhibitors or diuretics It is important to note that routine magnesium monitoring is not currently recommended in NICE guidance (NG28) for patients on GLP-1 therapy

I often come across one young TikToker who regularly hits back at her followers when they attempt to warn her of the damage she could be doing by using nasal sprays and patches

Traveling with GLP-1 medications requires advance planning to maintain proper storage conditions throughout the journey